Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chewy Inc (CHWY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Chewy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Chewy Inc trades at $22.57 (market cap $9.20B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.6× Chewy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.

CHWYVRTX
Market Cap
$9.20B$134.25B
Sector
Consumer CyclicalHealth
52-Week High
$42.33$529.65
52-Week Low
$17.51$376.62
Enterprise Value
$9.16B$128.37B

Returns comparison

Trailing returns across standard periods

About Chewy Inc

Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.

Read more on CHWY

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX